Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cetrimonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 8/20 | 0.75 |
| ▸ | APAF1 | O14727 | 1/20 | 0.68 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.68 |
| ▸ | RAD52 | P43351 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | APEX1 | P27695 | 3/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL27839094 | 1.00 | DNM1 (0.75) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Bicarbonate SCHEMBL28072724 | 1.00 | DNM1 (0.75) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Bicarbonate SCHEMBL27856897 | 1.00 | DNM1 (0.75) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Bicarbonate SCHEMBL27990803 | 1.00 | DNM1 (0.75) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Bicarbonate SCHEMBL5157446 | 1.00 | DNM1 (0.75) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Bicarbonate SCHEMBL17199718 | 1.00 | DNM1 (0.75) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Bicarbonate SCHEMBL28963225 | 1.00 | DNM1 (0.75) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Bicarbonate SCHEMBL9724758 | 1.00 | DNM1 (0.75) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Bicarbonate SCHEMBL17199724 | 1.00 | DNM1 (0.75) | DNM1APAF1HSP90AA1RAD52MEN1 | |
| Bicarbonate SCHEMBL26109031 | 1.00 | DNM1 (0.75) | DNM1APAF1HSP90AA1RAD52MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937369-B1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT, AND USE FOR SAID CATALYST | TOSOH CORP (JP) | 2020-11-11 | — | — | EP | claimed |
| US-20150344727-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT AND USE THEREOF | TOSOH CORPORATION (JP) | 2015-12-03 | — | — | US | claimed |
| EP-2937369-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT, AND USE FOR SAID CATALYST | Tosoh Corporation (JP) | 2015-10-28 | — | — | EP | claimed |
| CN-119817576-A | Low residue disinfectant wipe | 阿萨达有限责任公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119817577-A | Synergistic antimicrobial combinations comprising quaternary ammonium biocides | 阿萨达有限责任公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240277758-A1 | USE OF SODIUM THIOSULFATE FOR THE TREATMENT OF SULFUR MUSTARD EXPOSURE | HOPE MEDICAL ENTERPRISES, INC. DBA HOPE PHARMACEUTICALS (US) | 2024-08-22 | — | — | US | disclosed |
| CN-117157249-B | Cage silicate and method for producing same | 日产化学株式会社 | 2024-08-13 | — | — | CN | disclosed |
| WO-2024145314-A1 | USE OF SODIUM THIOSULFATE FOR THE TREATMENT OF SULFUR MUSTARD EXPOSURE | HOPE MEDICAL ENTERPRISES, INC. DBA HOPE PHARMACEUTICALS (US) | 2024-07-04 | — | — | WO | disclosed |
| US-12012368-B2 | Cage silicate and method for producing the same | NISSAN CHEMICAL CORPORATION (JP) | 2024-06-18 | — | — | US | disclosed |
| US-20240051913-A1 | CAGE SILICATE AND METHOD FOR PRODUCING THE SAME | NISSAN CHEMICAL CORPORATION (JP) | 2024-02-15 | — | — | US | disclosed |
| CN-117157249-A | Cage silicate and method for producing same | 日产化学株式会社 | 2023-12-01 | — | — | CN | disclosed |
| CN-105829375-B | Allophanate-isocyanurateing catalyst, polyisocyanate composition, method for producing the composition, and two-component coating composition | 东曹株式会社 | 2019-09-20 | — | — | CN | disclosed |
| CN-108658093-A | A kind of preparation method and applications of multi-stage porous ZSM-5 molecular sieve | 沈阳师范大学 | 2018-10-16 | — | — | CN | disclosed |
| CN-108431238-A | Method for preserving skin or skin | 阿切化学巴西有限公司 | 2018-08-21 | — | — | CN | disclosed |
| US-20150344727-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT AND USE THEREOF | TOSOH CORPORATION (JP) | 2015-12-03 | — | — | US | disclosed |
| EP-2937369-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT, AND USE FOR SAID CATALYST | Tosoh Corporation (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-5137923-A | Lipophilic quaternary ammonium salicylates, their use in cosmetics and in dermopharmacy | L'OREAL (FR) | 1992-08-11 | — | — | US | disclosed |
| US-5019567-A | Benzoyl peroxide--quaternary ammonium lipophilic salicylate based pharmaceutical and cosmetic compositions and their use especially in treatment of acne | L'OREAL (FR) | 1991-05-28 | — | — | US | disclosed |
| US-5001156-A | Lipophilic quaternary ammonium salicylates, their use in cosmetics and in dermopharmacy | L'OREAL (FR) | 1991-03-19 | — | — | US | disclosed |
| US-4857525-A | Quaternary ammonium retinoates, their use in cosmetics and in dermopharmacy | L'OREAL (FR) | 1989-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12012368-B2 | Cage silicate and method for producing the same | SIGMAR1, SAE1, SEM1 | DNM1 2035/4885APAF1 2111/4885HSP90AA1 2128/4885 |
| US-20240051913-A1 | CAGE SILICATE AND METHOD FOR PRODUCING THE SAME | ORAI2, SIGMAR1, SEM1 | DNM1 2074/4885APAF1 2248/4885HSP90AA1 2305/4885 |
| US-20240277758-A1 | USE OF SODIUM THIOSULFATE FOR THE TREATMENT OF SULFUR MUSTARD EXPOSURE | TST, MPST, STS | DNM1 4305/4885APAF1 3801/4885HSP90AA1 726/4885 |
| US-20150344727-A1 | QUATERNARY AMMONIUM SALT-CONTAINING CATALYST FOR DISSOCIATION OF BLOCKING AGENT AND USE THEREOF | CA2, KCNMB1, BET1 | DNM1 780/4885APAF1 2421/4885HSP90AA1 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.